Today’s Research Reports on Trending Tickers: AcelRx Pharmaceuticals and BioTelemetry
U.S. markets dropped Monday as geopolitical tensions between the U.S. and North Korea grew and as technology stocks slumped. The Dow Jones Industrial Average declined 0.24 percent to close at 22,296.09, while the S&P 500 Index fell 0.22 percent to close at 2,496.66. The tech-heavy Nasdaq Composite Index fell 0.88 percent to close at 6,370.59. Apple Inc., which is the Nasdaq’s largest component by market value, decline for the 4th consecutive session.
“Today is mostly about rotation from big-winning tech stocks and into losing energy and retail stocks, which is usually a healthy sign of the bull market,” said Michael Antonelli, equity sales trader at Robert W. Baird & Co.
“As we have seen before, any news from North Korea have an instant impact on markets, but usually it does not last,” Antonelli said.
RDI Initiates Coverage on:
AcelRx Pharmaceuticals Inc.
AcelRx Pharmaceuticals Inc.’s stock jumped 16.64% on Monday, to close the day at $3.91. The stock recorded a trading volume of 3,775,310 shares, which was above its three months average volume of 1,291,030 shares. In the last year AcelRx Pharmaceuticals Inc.’s shares have traded in a range of 1.95 – 4.08. The share price has gained 100.38% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. Moreover, the stock’s 50-day moving average of $3.08 is greater than its 200-day moving average of $2.80. Shares of AcelRx Pharmaceuticals have gained approximately 50 percent year-to-date.
Access RDI’s AcelRx Pharmaceuticals Inc. Research Report at:
On Monday, shares in BioTelemetry Inc. recorded a trading volume of 924,733 shares, which was above the three months average volume of 478,847 shares. The stock ended the day 2.19% lower at 31.30. The share price has gained 105.25% from its 52 week low with a 52 week trading range of 15.25 – 39.20.The company’s shares are currently trading below their 200-day moving average. Moreover, the stock’s 50-day moving average of $35.68 is greater than its 200-day moving average of $31.50. Shares of BioTelemetry Inc. are trading at a Price to Earnings ratio of 21.01. Shares of BioTelemetry have gained approximately 39.82 percent year-to-date.
Access RDI’s BioTelemetry Inc. Research Report at:
Our Actionable Research on AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) and BioTelemetry Inc. (NASDAQ:BEAT) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.